Vaccine Adjuvants Market Analysis & Opportunity Outlook 2023-2035

Global Vaccine Adjuvants Market Size, Forecast, and Trend Highlights Over 2023 – 2035

The global vaccine adjuvants market size is estimated to reach ~USD 4 Billion by the end of 2035 by growing at a CAGR of ~4.70% over the forecast period, i.e., 2023 – 2035. In addition to this, in the year 2022, the market size of vaccine adjuvants was ~USD 2 Billion. The growth of the market can be attributed to the growing prevalence of infectious and allergy diseases such as HIV/AIDS, tuberculosis (TB), malaria, and neglected infectious diseases along with increasing demand for advanced and improved vaccines. NTDs encompass a diverse group of infections caused by parasites, bacteria, fungi, viruses, and other non-communicable pathogens. In addition, there were 1.6 million deaths from TB in 2021 (including 187 000 HIV-positive individuals). According to the World Health Organization, TB is the 13th leading cause of death and the second leading infectious killer in the world after COVID-19. Vaccine adjuvants are substances that improve the effectiveness of vaccines. The growing prevalence of infectious diseases has caused an increase in demand for more effective vaccines, which has in turn contributed to greater research and development of new vaccine adjuvants.

In addition to these, factors that are believed to fuel the market growth of vaccine adjuvants include an increase in financial support from governments and private organizations for the development of vaccines and the growing demand for safe and effective immunization are expected to have a positive impact on the growth of the global vaccine adjuvants market. In addition, funding for vaccine research and infectious disease research is expected to enhance the lucrative prospects for vaccine adjuvants. For instance, to prevent epidemics, detect disease threats, and respond rapidly and effectively to epidemics, the US government announced a funding of USD 122 million for Indian medical research institutes in June 2022.

Global Vaccine Adjuvants Market: Growth Drivers and Challenges

Growth Drivers

Rising Number of Government Initiatives to Promote Vaccination and Support the Development of New Vaccines - For instance, a National Strategic Plan (2021-2025) for vaccines and immunizations provide a vision for the future of the U.S. vaccine and immunization enterprise. US Healthy People 2030 initiative focuses on increasing vaccination rates to prevent infectious diseases. This initiative seeks to increase public awareness around the importance of vaccination and its role in the prevention of infectious diseases. Moreover, Indian government's vaccination initiatives such as Har Ghar Dastak and Jan Bhagidari Andolan have been successful in immunizing large sections of the population, especially in rural areas where access to healthcare is scarce. As a result, there has been a significant reduction in the prevalence of vaccine-preventable diseases.
Growing Cases of Seasonal Influenza - Seasonal influenza causes between -3 million and 5 million severe illnesses and between 290,000 and 650,000 respiratory deaths per year, according to the World Health Organization. As the number of influenza cases increase, so does the need for more effective influenza vaccines. Vaccine adjuvants are substances added to vaccines to enhance their effectiveness, making them better able to protect against the virus.
Increase in the Number of HIV/AIDS Cases - According to the Centers for Disease Control and Prevention (CDC), there were an estimated 1,189,700 HIV-positive individuals in the United States as of the end of 2019. HIV is most prevalent among black and African American people. The number of new HIV diagnoses among Black/African American people in 2020 was 42 percent (12,827).
High Prevalence Chronic Diseases Such as Cancer have Prompted a Surge in the Demand for Vaccine Adjuvants- Vaccine adjuvants are used to enhance the body's immune response to the cancer cells, allowing the body to mount a stronger attack against the cancer cells. This can help to reduce the growth of the tumor and even eliminate it altogether. Thus, the rising prevalence of cancer is expected to drive market growth. The World Health Organization estimates that cancer caused nearly 10 million deaths worldwide in 2020. Among the most common cancers are breast, lung, colon, and rectum cancers as well as prostate cancer.
Increasing Development and Approval of Several COVID-19 Vaccines - For instance, Novavax COVID-19 Vaccine, adjuvanted for the prevention of COVID-19 in individuals 18 years of age and older, was approved by the United States Food and Drug Administration in July 2022 as an emergency use authorization (EUA).

Challenges

Long approval process - Vaccines are heavily regulated, and the approval process can be lengthy and complex. This can delay the availability of new vaccines and even cause existing vaccines to be taken off the market. The lengthy approval process can also make it difficult for new companies to enter the market.
High cost of vaccine adjuvants
Complexities associated with the development of vaccine adjuvants, as well as stringent regulatory requirements

Global Vaccine Adjuvants Market Segmentation

The global vaccine adjuvants market is segmented and analyzed for demand and supply by product type into adjuvant emulsions, pathogen components, saponin-based adjuvants, particulate adjuvants and others. Out of these, the adjuvant emulsions segment is estimated to gain the largest market share of about ~29% in the year 2035. The increasing demand for adjuvant emulsions in the vaccine market owing to their capability to enhance the efficacy of the vaccine, as well as the rising awareness about the importance of immunization among the population are major factors driving the growth of this segment. For instance, a number of emulsion adjuvants have been used in commercially available influenza vaccines, such as MF59 and AS03, and their composition and performance have been extensively studied and reported. Moreover, increasing government initiatives to promote the use of adjuvant-containing vaccines to reduce the cost of the vaccine delivery system and enhance the overall efficiency of the vaccine are also contributing to the growth of this segment.

The global vaccine adjuvants market is segmented and analyzed for demand and supply by route of administration into intramuscular, subcutaneous, oral route and others. Out of these, the intramuscular segment is estimated to gain the significant market share of about ~37% in the year 2035. The intramuscular route of administration is becoming increasingly popular among the patient population owing to its ability to provide a more sustained release of the vaccine, thereby improving the efficiency of the vaccine. Research has shown that 30 to 50% of intended intramuscular injections succeed, with the remainder resulting in inadvertent subcutaneous drug placement. Additionally, intramuscular injections are considered to be less painful than other routes of administration, making them more desirable for patients. These factors are anticipated to create numerous opportunities for the growth of the segment in the coming years.

Our in-depth analysis of the global vaccine adjuvants market includes the following segments:

By Product Type	Adjuvant Emulsions Pathogen Components Saponin-based Adjuvants Particulate Adjuvants Others
By Route of Administration	Intramuscular Subcutaneous Oral Route Others
By Disease Type	Infectious Diseases Cancer Others
By Application	Research Application Commercial Application
By Application Category	Human Vaccine Adjuvants Veterinary Vaccine Adjuvants

Global Vaccine Adjuvants Market Regional Synopsis

The market share of vaccine adjuvants in North America, amongst the market in all the other regions, is projected to be the largest with a share of about ~35% by the end of 2035. The growth of the market can be attributed majorly to the large population of elderly individuals and the increasing prevalence of chronic diseases, such as cancer, diabetes, and heart disease. Vaccine adjuvants enhance the immune system's response to the vaccine, resulting in a stronger and more effective response. With high recommendations for children’s vaccines, the demand for vaccine adjuvants in North America is expected to increase. For instance, United States standard recommendations include 10 vaccines for children between the ages of birth and 10 including hepatitis A (HepA); hepatitis B (HepB); RV; diphtheria, tetanus, and others. Additionally, increasing awareness about the importance of vaccinations, advances in vaccine technologies such as mRNA, and the growing adoption of preventive healthcare measures are likely to drive the growth of the market in this region. mRNA vaccines have revolutionized the speed of development and deployment of vaccines. mRNA vaccines are based on messenger RNA which provides instructions to cells to produce proteins that stimulate an immune response. These factors are anticipated to boost the market growth during the forecast period.

The Asia Pacific vaccine adjuvants market is estimated to be the second largest, registering a share of about ~24% by the end of 2035. The growth of the market can be attributed majorly to the increased investment in vaccine research and development as well as the growing demand for combined vaccines. It was observed that a total of over USD 1 billion has been invested in Chinese vaccine research and development. A further 11.35 million doses of Covishield were exported by India in the year 2021. These doses were sent to 92 countries, including health workers and peacekeepers from the UN. Additionally, the rising prevalence of lifestyle-related diseases such as cancer and diabetes, as well as high prevalence of infectious diseases such as malaria and dengue, are expected to drive the demand for vaccines in the region, thus driving the growth of the vaccine adjuvant market in the Asia Pacific region.

Further, the vaccine adjuvants market in the Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The growth of the market can be attributed majorly to the presence of a large number of vaccine manufacturers in the region and the increasing government support for vaccination programs. Additionally, Europe is also witnessing an increase in the prevalence of chronic diseases resulting in an increase in vaccine demand. Vaccines work by introducing a weakened or inactive form of a virus or bacteria into the body, prompting the immune system to produce antibodies and build immunity. Adjuvants are added to vaccines to enhance the body’s immune response and to reduce the amount of the active ingredient, or antigen, needed in a vaccine. This makes them more effective at combating chronic diseases and are anticipated to boost the market growth during the forecast period.

Get more information on this report: Request Free Sample PDF

Top Featured Companies Dominating the Global Vaccine Adjuvants Market

Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

GSK plc
SK Bioscience
Sanofi
Abbott
Phibro Animal Health Corporation
Astrazeneca
Novavax, Inc.
Agenus Inc.
Astellas Pharma Inc.

In The News

As the basis for their applications for regulatory approval, Sanofi and GSK plc intend to submit data from their booster and Phase 3 efficacy trials. The data they plan to submit is expected to include the full results of their Phase 3 efficacy trial of the vaccine, as well as data from their booster trial, which is designed to assess the efficacy of the vaccine after a booster dose.
GSK plc and SK Bioscience have submitted an application for a biologics license to the Korean Ministry of Food and Drug Safety for their SKYCovione after receiving positive Phase III clinical results. It is a candidate COVID-19 vaccine based on recombinant protein that has been adjuvant with GSK's pandemic adjuvant.

Global Economic Impact

Request Insights

Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the vaccine adjuvants market?

Ans: The increasing prevalence of infectious diseases and the growing demand for safe and effective vaccines are the major factors driving the market growth.

2) What would be the CAGR of vaccine adjuvants market over the forecast period?

Ans: The market size of vaccine adjuvants is anticipated to attain a CAGR of ~4.70% over the forecast period, i.e., 2023 – 2035.

3) What are the challenges affecting the vaccine adjuvants market growth?

Ans: High cost of vaccine adjuvants and the complexities associated with their development, as well as stringent regulatory requirements are estimated to be the growth hindering factors for the market expansion.

4) Which region will provide more business opportunities for growth of vaccine adjuvants market in future?

Ans: The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

5) Who are the major players dominating the vaccine adjuvants market?

Ans: The major players in the market are Pfizer Inc., GSK plc, SK Bioscience, Sanofi, Abbott, Phibro Animal Health Corporation, Astrazeneca, Novavax, Inc., Agenus Inc., Astellas Pharma Inc.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the vaccine adjuvants market?

Ans: The market is segmented by product type, route of administration, disease type, application, application category and by region.

8) Which segment captures the largest market size in the product type segment in the vaccine adjuvants market?

Ans: The adjuvant emulsions segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Base Year	2022
Forecast Year	2023-2035
CAGR	~4.70%
Base Year Market Size (2022)	~ USD 2 Billion
Forecast Year Market Size (2035)	~ USD 4 Billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)